This Journal Watch summarizes the study titled “Effect of Tacrolimus vs Intravenous Cyclophosphamide on Complete or Partial Response in Patients with Lupus Nephritis: A Randomized Clinical Trial”, published in the JAMA Network Open in March 2022. Highlights: Lupus nephritis is an inflammatory disorder of the kidneys due to systemic lupus erythematosus, an autoimmune disease. Oral tacrolimus is more effective in treating lupus nephritis, with patients showing an improvement in kidney function and a lower incidence of adverse events Need for this study: Systemic lupus erythematosus (SLE) is an autoimmune disease with an estimated global incidence rate of 20-60 per 100,000 population.
This disease affects multiple organs; around 50% of patients can develop lupus nephritis. Current treatment options include intravenous cyclophosphamide (IVCY) with corticosteroids like prednisone. However,…
